{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:30:40Z","timestamp":1778211040490,"version":"3.51.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10875-023-01639-9","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T10:02:04Z","timestamp":1703239324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["IL-4R\u03b1 Inhibition for Severe \u201cEosinophilic Gastroenteritis, Allergy, and Anaphylaxis\u201d Syndrome due to a Gain-of-Function Variant in STAT6"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-0927","authenticated-orcid":false,"given":"Stanislas","family":"Faguer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Delabesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marl\u00e8ne","family":"Pasquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"issue":"2","key":"1639_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaci.2022.09.028","volume":"151","author":"N Suratannon","year":"2023","unstructured":"Suratannon N, Ittiwut C, Dik WA, Ittiwut R, Meesilpavikkai K, Israsena N, et al. A germline STAT6 gain-of-function variant is associated with early-onset allergies. J Allergy Clin Immunol. 2023;151(2):565-571.e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1639_CR2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.jaci.2022.12.802","volume":"151","author":"I Takeuchi","year":"2023","unstructured":"Takeuchi I, Yanagi K, Takada S, Uchiyama T, Igarashi A, Motomura K, et al. STAT6 gain-of-function variant exacerbates multiple allergic symptoms. J Allergy Clin Immunol. 2023;151(5):1402-1409.e6.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1639_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jaci.2023.01.023","volume":"152","author":"S Baris","year":"2023","unstructured":"Baris S, Benamar M, Chen Q, Catak MC, Mart\u00ednez-Blanco M, Wang M, et al. Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6. J Allergy Clin Immunol. 2023;152(1):182-194.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1639_CR4","doi-asserted-by":"publisher","first-page":"e20221755","DOI":"10.1084\/jem.20221755","volume":"220","author":"M Sharma","year":"2023","unstructured":"Sharma M, Leung D, Momenilandi M, Jones LCW, Pacillo L, James AE, et al. Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease. J Exp Med. 2023;220(5):e20221755.","journal-title":"J Exp Med."},{"issue":"7","key":"1639_CR5","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s10875-023-01530-7","volume":"43","author":"E Minskaia","year":"2023","unstructured":"Minskaia E, Maimaris J, Jenkins P, Albuquerque AS, Hong Y, Eleftheriou D, et al. Autosomal Dominant STAT6 Gain of Function Causes Severe Atopy Associated with Lymphoma. J Clin Immunol. 2023;43(7):1611\u201322.","journal-title":"J Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01639-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01639-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T09:21:59Z","timestamp":1706692919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01639-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1639"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01639-9","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"23 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"This study was conducted according to the Declaration of Helsinki (2004). The patient\u2019s oral consent to be included in the Nephrogene cohort (biological collection approved by the French National Ethics Committee; N\u00b0 DC-2011\u2013138) and that her case was reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"SF received fees for scientific advisory boards, lectures, and consultating from Abionyx Pharma, Genzyme-Sanofi, CSL-Vifor, GlaxoSmithKline, AstraZeneca-Alexion, and Baxter. CP has received grants and has been consultant for Almirall, Amgen, Abbvie, Apogee therapeutics, BMS, Boehringer, Celgene, Galderma, GlaxoSmithKline, Eli Lilly, Iqvia, Janssen, Leo Pharma, Merck, Mylan, Novartis, Pfizer, Pierre Fabre, Sanofi, and UCB pharma. ED and MP declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"29"}}